Is nuclear expression of Y box‐binding protein‐1 a new prognostic factor in ovarian serous adenocarcinoma?
暂无分享,去创建一个
K. Kohno | M. Kuwano | H. Nakano | S. Amada | T. Kamura | H. Kobayashi | S. Ogawa | H. Yahata | M. Mitsumoto | Takanori Sonoda | Masamune Mitsumoto
[1] Y. Iwamoto,et al. Nuclear expression of YB-1 protein correlates with P-glycoprotein expression in human osteosarcoma. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[2] K. Kohno,et al. Direct Involvement of the Y-box Binding Protein YB-1 in Genotoxic Stress-induced Activation of the Human Multidrug Resistance 1 Gene* , 1998, The Journal of Biological Chemistry.
[3] X. Chen,et al. [The expression of glutathione S-transferase pi in human ovarian cancer as an indicator of resistance to chemotherapy]. , 1998, Zhonghua fu chan ke za zhi.
[4] K. Kohno,et al. Nuclear translocation of the Y‐box binding protein by ultraviolet irradiation , 1997, FEBS letters.
[5] F. Oesch,et al. Glutathione, GlutathioneS-Transferase α and π, and Aldehyde Dehydrogenase Content in Relationship to Drug Resistance in Ovarian Cancer , 1997 .
[6] F. Oesch,et al. Glutathione, glutathione S-transferase alpha and pi, and aldehyde dehydrogenase content in relationship to drug resistance in ovarian cancer. , 1997, Gynecologic oncology.
[7] B. Dörken,et al. Nuclear localization and increased levels of transcription factor YB-1 in primary human breast cancers are associated with intrinsic MDR1 gene expression , 1997, Nature Medicine.
[8] M. Tanimoto,et al. Role of the human Y box-binding protein YB-1 in cellular sensitivity to the DNA-damaging agents cisplatin, mitomycin C, and ultraviolet light. , 1996, Cancer research.
[9] K. Kohno,et al. A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation. , 1996, Cancer research.
[10] J. Yodoi,et al. Cellular levels of thioredoxin associated with drug sensitivity to cisplatin, mitomycin C, doxorubicin, and etoposide. , 1995, Cancer research.
[11] M. Tsuneyoshi,et al. Leiomyosarcoma Versus Bizarre and Cellular Leiomyomas of the Uterus: A Comparative Study Based on the MIB‐1 and Proliferating Cell Nuclear Antigen Indices, p53 Expression, DNA Flow Cytometry, and Muscle Specific Actins , 1995, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.
[12] K. Kohno,et al. Increased expression of DNA topoisomerase I gene and collateral sensitivity to camptothecin in human cisplatin-resistant bladder cancer cells. , 1994, Cancer research.
[13] J. Berek,et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. , 1994, American journal of obstetrics and gynecology.
[14] H. Furumoto,et al. Expression of glutathione S‐transferase‐π in human ovarian cancer as an indicator of resistance to chemotherapy , 1994, Gynecologic oncology.
[15] K. Kohno,et al. Reduction of drug accumulation in cisplatin-resistant variants of human prostatic cancer PC-3 cell line. , 1993, The Journal of urology.
[16] T. Ishikawa,et al. Glutathione-associated cis-diamminedichloroplatinum(II) metabolism and ATP-dependent efflux from leukemia cells. Molecular characterization of glutathione-platinum complex and its biological significance. , 1993, The Journal of biological chemistry.
[17] K. Kohno,et al. Enhanced expression of the human multidrug resistance 1 gene in response to UV light irradiation. , 1993, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.
[18] A. Godwin,et al. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[19] N. Saijo,et al. Metallothionein content correlates with the sensitivity of human small cell lung cancer cell lines to cisplatin. , 1991, Cancer research.
[20] C. Yan,et al. Molecular cloning and characterization of interferon alpha/beta response element binding factors of the murine (2'-5')oligoadenylate synthetase ME-12 gene. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[21] S. Kato,et al. Tissue-specific enhancer of the human multidrug-resistance (MDR1) gene. , 1990, The Journal of biological chemistry.
[22] A. Fojo,et al. Increased DNA repair as a mechanism of acquired resistance to cis-diamminedichloroplatinum (II) in human ovarian cancer cell lines. , 1988, Cancer research.
[23] D. K. Didier,et al. Characterization of the cDNA encoding a protein binding to the major histocompatibility complex class II Y box. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[24] A. Eastman,et al. Enhanced DNA repair as a mechanism of resistance to cis-diamminedichloroplatinum(II). , 1988, Biochemistry.
[25] S. Howell,et al. cis-Diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells. , 1988, Cancer research.
[26] E. Wiltshaw,et al. Phase II study of cis-dichlorodiammineplatinum(II) (NSC-119875) in advanced adenocarcinoma of the ovary. , 1976, Cancer treatment reports.